CHANGSHA GUANXIN TECHNOLOGY CO., LTD – Trademark Portfolio

Entity Type: 22

CHANGSHA GUANXIN TECHNOLOGY CO., LTD holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include EOCUTE. The owner is based in CHANGSHA CITY.

ROOM 2605, AREA A, BUILDING 14, JIN YUE YAYUAN PHASE II COMMERCIAL BUILDING, NO.268 LUYUN ROAD, TIANDING STREET, YUELU DISTRICT

CHANGSHA CITY 410000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

EOCUTE
EOCUTE
Registered 2020

Trademark Classifications

CHANGSHA GUANXIN TECHNOLOGY CO., LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does CHANGSHA GUANXIN TECHNOLOGY CO., LTD have?

CHANGSHA GUANXIN TECHNOLOGY CO., LTD has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does CHANGSHA GUANXIN TECHNOLOGY CO., LTD file in?

CHANGSHA GUANXIN TECHNOLOGY CO., LTD files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are CHANGSHA GUANXIN TECHNOLOGY CO., LTD's most well-known trademarks?

CHANGSHA GUANXIN TECHNOLOGY CO., LTD's registered trademark portfolio includes well-known marks such as EOCUTE. These are among 1 currently registered trademark in the portfolio.

What is CHANGSHA GUANXIN TECHNOLOGY CO., LTD's trademark registration success rate?

CHANGSHA GUANXIN TECHNOLOGY CO., LTD has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.